Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel anticonvulsant medications in development.

Collin A Hovinga1

  • 1Department of Pharmacy, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA. hovingc@ccf.org

Expert Opinion on Investigational Drugs
|October 22, 2002
PubMed
Summary

Next-generation anticonvulsants aim to overcome limitations of current epilepsy drugs. These novel treatments offer improved efficacy, tolerability, and new mechanisms for refractory epilepsy patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating Kidney Function Decline in Children with Chronic Kidney Disease Using a Multi-Institutional Electronic Health Record Database.

Clinical journal of the American Society of Nephrology : CJASN·2023
Same author

Efficacy and patient opinion of wet-wrap dressings using 0.1% triamcinolone acetonide ointment vs cream in the treatment of pediatric atopic dermatitis: A randomized split-body control study.

Pediatric dermatology·2019
Same author

Association Between Delusions of Infestation and Prescribed Narcotic and Stimulant Use.

Journal of psychiatric practice·2018
Same author

Thrombolysis in pediatric stroke study.

Stroke·2015
Same author

Emergence of the primary pediatric stroke center: impact of the thrombolysis in pediatric stroke trial.

Stroke·2014
Same author

Epigenetic analysis of neurocognitive development at 1 year of age in a community-based pregnancy cohort.

Behavior genetics·2014

Area of Science:

  • Neurology
  • Pharmacology
  • Drug Discovery

Background:

  • Epilepsy is a widespread neurological disorder, with refractory cases posing significant treatment challenges.
  • Current anticonvulsants often fail due to limited efficacy and side effects, partly because they share similar mechanisms of action.
  • Existing treatments do not address epilepsy development (epileptogenesis) or individual pathophysiological variations.

Purpose of the Study:

  • To review the next generation of anticonvulsant therapies.
  • To discuss novel drugs designed with improved chemical structures, delivery, pharmacokinetic properties, and mechanisms of action.
  • To identify potential clinical applications for these investigational anticonvulsants.

Main Methods:

  • Review of investigational anticonvulsants.
  • Discussion of drug design rationale, including improved tolerability and pharmacokinetics.
  • Analysis of novel mechanisms of action or combinations thereof.

Main Results:

  • The next generation of anticonvulsants is being developed using rational drug design.
  • These agents aim for enhanced tolerability, new or combined mechanisms of action, and improved pharmacokinetic profiles.
  • Specific examples include carabersat, CGX-1007, fluorofelbamate, harkoseride, losigamone, pregabalin, retigabine, safinamide, SPD-421, talampanel, and valrocemide.

Conclusions:

  • Next-generation anticonvulsants represent a significant advancement in epilepsy pharmacotherapy.
  • These drugs are designed to address the shortcomings of current treatments, offering hope for patients with refractory epilepsy.
  • Further research will define the specific patient populations that will benefit most from these novel therapies.

Related Experiment Videos